Edwards Lifesciences (EW) Tops Q1 EPS by 6c, Revenues Beat; Offers FY21 EPS Outlook
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Edwards Lifesciences (EW) PT Raised to $105 at Piper Sandler
April 21, 2021 9:22 AM EDTPiper Sandler analyst Adam Maeder raised the price target on Edwards Lifesciences (NYSE: EW) to $105.00 (from $97.00) while maintaining a Overweight rating.
... MoreEdwards Lifesciences (EW) PT Raised to $103 at Canaccord Genuity
April 21, 2021 8:26 AM EDTCanaccord Genuity analyst Jason Mills raised the price target on Edwards Lifesciences (NYSE: EW) to $103.00 (from $94.00) while maintaining a Buy rating.
The analyst commented, "EW Q1/21 revenue of $1,217M (+7.8% GAAP Y/Y; +5.0% adjusted CC),beat our estimate of $1,176M and consensus of $1,162M. There was positive Y/Y growth from... More
Edwards Lifesciences (EW) PT Raised to $103 at Stifel
April 21, 2021 8:16 AM EDTStifel analyst Rick Wise raised the price target on Edwards Lifesciences (NYSE: EW) to $103.00 (from $100.00) while maintaining a Buy rating.
The analyst commented, "Overall, Edwards better-than-expected 1Q21 results marked a solid start to 2021, and post-release recovery trend/guidance commentary left us feeling... More
Edwards Lifesciences (EW) PT Raised to $110 at Jefferies
April 21, 2021 8:09 AM EDTJefferies analyst Raj Denhoy raised the price target on Edwards Lifesciences (NYSE: EW) to $110.00 (from $105.00) while maintaining a Buy rating.
The analyst commented, "EW posted $60mn/$0.07 beat with US TAVR flat offset by a rebound OUS to low DDs(HSD in... More